An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Study Identifier:
ECU-NMO-302
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: eculizumab
Date
Jan 2015 - Jul 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: eculizumab
Date
Jan 2015 - Jul 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
Trial Locations
Location
Status
Location
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259
Status
N/A
Location
The Research Center of Southern California
Oceanside, California, United States, 92056
Status
N/A
Location
Georgetown University Hospital
Washington, District of Columbia, United States, 20007
Status
N/A
Location
University of Miami McKnight Brain Institute
Miami, Florida, United States, 33136
Status
N/A
Location
Neurological Services of Orlando
Orlando, Florida, United States, 32806
Status
N/A
Location
Allied Physicians Inc. of Fort Wayne
Fort Wayne, Indiana, United States, 46805
Status
N/A